Showing results (61-70 of 118) with videos related to
Sort By:
Pageof 12
International Journal of Cancer|March 23, 2000
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layersJ K Tunggal, T Melo, J R Ballinger, et al.Journal of Nuclear Medicine Technology|June 3, 1999
External radioactive reference markers in SPECT imaging of the dopamine systemD C Vines, B D Ivo, J R Ballinger, et al.Journal of Cutaneous Medicine and Surgery|September 26, 2000
Malignant melanoma in a patient with oculocutaneous albinismC J Streutker, D McCready, K Jimbow, et al.CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 14, 2001
Appropriate procedures for the safe handling and pathologic examination of technetium-99m-labelled specimensT J Colgan, D Booth, A Hendler, et al.Breast Cancer Research and Treatment|December 7, 2005
The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancerM C Gainford, D McCready, Z Cohen, et al.Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|November 1, 1987
Neostigmine, pyridostigmine and edrophonium as antagonists of deep pancuronium blockadeF Donati, J Lahoud, D McCready, et al.Annals of Nuclear Medicine|February 1, 1993
Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humansH Toyama, M Ichise, J R Ballinger, et al.Clinical Nuclear Medicine|June 1, 1990
Cerebral perfusion imaging with technetium-99m HMPAO following cerebral trauma. Initial experienceR H Reid, K Y Gulenchyn, J R Ballinger, et al.British Journal of Urology|February 1, 1995
A novel anti-seminoma monoclonal antibody (M2A) labelled with technetium-99m: potential application for radioimmunoscintigraphyA Marks, J R Ballinger, R M Reilly, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 1993
Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's diseaseM Ichise, H Toyama, L Fornazzari, et al.Pageof 12